As of the press release on January 29, wind data shows that among the 258 ** biomedical listed companies included in the statistics, 54 have successively disclosed their 2023 performance forecasts. Among them, 29 companies are expected to increase, 8 companies have turned losses, and 13 companies have announced that the lower limit of net profit year-on-year growth exceeds 100%.
At the same time, Mindray Medical, Tigermed and other leading biopharmaceutical companies actively leverage the capital market to make themselves better and stronger through market-oriented mergers and acquisitions, and continue to enhance their core competitiveness.
The main business has grown steadily, and the performance of many leading companies has "increased".
On the evening of January 28, the leading CRO Pharmaron and the health examination industry leader Meinian Health Performance Forecast were released. Specifically, Pharmaron expects to achieve operating revenue of 113$9.6 billion to $1170.4 billion yuan, a year-on-year increase of 11% to 14%; Net profit attributable to the parent company 15$6.7 billion to $163.6 billion yuan, a year-on-year increase of 14% to 19%. Regarding the performance growth, Pharmaron said that during the reporting period, the revenue of each company's business segment increased steadily, and the overall profit of the main business increased.
Another company, Meinian Health, has achieved a year-on-year turnaround. The company expects to achieve an operating income of 107 in 2023300 million yuan to 110 million500 million yuan, an increase of 21 over the same period last year$9.7 billion to $251.7 billion yuan, a year-on-year increase of 2575% to 2950%；Net profit attributable to the parent company 4600 million to 5700 million yuan, an increase of 186 over the previous year28% to 20691%。"During the reporting period, the diversified and personalized health needs continued to grow for a long time, the health consumption willingness and consumption frequency of individuals and groups increased significantly, and they were willing to pay for high-quality health services, and there was a strong demand for special examinations for chronic underlying diseases and mid-to-high-end health management, and they hoped to obtain a better service experience. Meinian Health introduced that the company provides customers with personalized and customized in-depth product experience, and continuously increases the proportion of high-end customers. The company also continuously strengthened the B-end business upgrade led by government and enterprise customers, actively promoted the full implementation of the group and regional linkage model, rapidly promoted the C-end customer operation system, and made efforts to expand the local life business of Meinian Selected Distribution**, Meituan, and Douyin.
Benefiting from the release of market demand, the net profit of some listed companies has doubled.
In addition to Meinian Health, among the 13 listed companies that "forecast a year-on-year increase in net profit of more than 100%", many companies such as Preh Ophthalmology and Kangtai Biotechnology have also performed well in the past year.
According to the 2023 performance forecast disclosed by Kangtai Biotech, the company is expected to achieve a net profit of about 8500 million to 9500 million yuan, a year-on-year increase of 74050% to 81586%。According to reports, the company has carried out various forms of vaccine cooperation with Pakistan, Indonesia, Saudi Arabia, India and other countries, and jointly promoted the registration, listing and commercialization of important products such as 13-valent and 23-valent pneumonia vaccines and chickenpox vaccines overseas. Among them, the 13-valent pneumococcal vaccine has been approved for overseas marketing in Indonesia, and it is expected to form a formal order for export sales.
In 2023, Preh Ophthalmology seized the opportunity of consumption recovery and the increasing demand for eye health from patients, and its overall performance returned to rapid growth. After preliminary accounting, the company expects to achieve operating income of 26 in 20238 billion to 271 billion yuan, a year-on-year increase of 5530% to 5704%；Achieved net profit attributable to the parent company of 26 billion to 28.5 billion yuan, a year-on-year increase of 116398% to 128551%；Realize the net profit of 18 billion to 20.5 billion yuan, a year-on-year increase of 87087% to 100572%。As for the main reason for the pre-increase in performance, Preh Ophthalmology said that the performance contribution of the company's mature hospitals is the most important factor for the company's overall performance growth. At the beginning of 2023, the company completed the merger and acquisition of Dongguan Guangming Eye Hospital and included it in the scope of consolidated statements, and its good performance made a great contribution to the company's overall profit growth. In addition, in 2023, some of the company's hospitals have achieved breakeven or further reduced losses after the incubation period, which has also made a certain contribution to the company's performance growth. In addition, the company strictly controls costs and expenses, reduces costs and increases efficiency, and effectively improves the company's profit margin.
Market-oriented mergers and acquisitions continue to be better and stronger.
While grasping market opportunities, ** biomedical companies also actively use market-oriented means to continuously become better and stronger. On the evening of January 28, an announcement by Mindray Medical, a leading domestic medical device company and a GEM company, attracted market attention. According to the announcement, Mindray Medical spent 66500 million yuan, through the "agreement transfer + voting rights" to acquire the equity of another subdivision leader, Huitai Medical, and quickly lay out the subdivision track in the cardiovascular field. If the full acquisition plan is successfully implemented, Mindray Medical will hold a total of 2461% of the shares, becoming the largest shareholder of Huitai Medical.
Industry insiders said that for a long time, the medical device field has always shown the characteristics of a strong and strong industry, coupled with the large number of subdivided tracks and limited technology and channel synergy between tracks, after the development of enterprises in the industry has entered a certain stage, they need to rely on epitaxial mergers and acquisitions to cultivate new growth points and continue to expand business boundaries, which is also true for Mindray Medical, the industry leader. The combined competitive advantage and cost-effective advantage brought by the strong alliance are becoming a direct weapon for the two companies' products to break through the global market. The industrial integration of complementary resources is also expected to give birth to new leaders in the industry, starting from the cardiovascular track to open up a broader market for domestic medical devices.
Chen Zhu, chief analyst of CITIC ** medical and health industry, said that the merger and acquisition shows that the value and long-term growth of the relevant leading companies in the A-share medical and health sector are still very certain. As a leading enterprise in the biomedical sector, Mindray Medical seized the opportunity to make corresponding acquisitions and layouts, highlighting that there are more value targets to be tapped in A-shares, and it may integrate industrial resources with leading enterprises in the future. This logic will not change in the long term. In the future, looking at the entire A** field, enterprises with sufficient cash reserves will also enter the upgrading stage of excellent resource integration and accelerated growth of leading enterprises in this way.
In addition to Mindray, Tigermed, one of the first CRO providers in China to provide several clinical trial-related services, has also continuously improved the synergy of the company's overseas business and clinical operations through mergers and acquisitions. In early 2023, the Company completed the acquisition of Martin Farm. This move further strengthens the company's service capabilities and scale in Europe, enhances the company's pharmacovigilance globalization and integration service capabilities, and further improves the company's ability to provide high-quality clinical services for global customers in Europe. According to public information, Martin Farm is a clinical contract research organization (CRO) that provides professional services such as pharmacovigilance, clinical operations, medical translation, registration and medical affairs to clients in Europe and around the world. Up to now, Tigermed has 29 major overseas subsidiaries or branches. Tigermed previously said that in the future, the company will also carry out global business development through team expansion or mergers and acquisitions, create differentiated competitive advantages in Europe, America and emerging regional markets, and gradually improve its global operation capabilities. (Reporter Wei Xiayi reports from Beijing).
Editor: Luo Yishu.